Gilead sales and marketing update

Starting next half, Gilead will provide HCV drug Sovaldi sofosbuvir in Egypt at $300 for a four-week supply - or $900 for a 12-week course of therapy - after finalizing an agreement with the country's National Liver Committee. According to Gilead, Egypt has the highest prevalence rate of HCV in the world. The wholesale acquisition cost (WAC) for a 12-week course of Sovaldi in the U.S. is $84,000. FDA and Health Canada approved Sovaldi in December. The European Commission approved the nucleotide analog HCV NS5B polymerase inhibitor to treat chronic HCV infection in January (see BioCentury, Jan. 20). ...